Quantcast
Last updated on April 17, 2014 at 8:56 EDT

Latest Sirolimus Stories

2012-06-01 09:27:49

New study creates cells that act like circuits, a step toward developing cellular computers Johns Hopkins scientists have engineered cells that behave like AND and OR Boolean logic gates, producing an output based on one or more unique inputs. This feat, published in the May issue of Nature Chemical Biology, could eventually help researchers create computers that use cells as tiny circuits. Study leader Takanari Inoue, Ph.D., an assistant professor in the Department of Cell Biology and...

2012-05-17 09:28:23

A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients. In addition, the Georgetown Lombardi Comprehensive Cancer Center researchers conducting the study in cancer patients whose tumors have resisted multiple treatments say the combination demonstrates "promising evidence" of disease control and should be studied in a phase II trial. Their clinical findings and additional data...

2012-05-17 02:25:54

PARIS, May 17, 2012 /PRNewswire/ -- OrbusNeich today announced that two subgroup analyses from the REMEDEE trial assessing vascular healing of the company's Combo Dual Therapy Stent versus the TAXUS paclitaxel-eluting stent demonstrate an early advantage with the Combo Stent. Presented at EuroPCR 2012, the data were obtained with frequency-domain optical coherence tomography (FD-OCT) and virtual histology-intravascular ultrasound (VH-IVUS) at nine-month follow-up. An independent OCT core...

2012-05-15 10:24:43

PARIS, May 15, 2012 /PRNewswire/ -- OrbusNeich today announced that 12-month follow-up data from the REMEDEE study showed favorable clinical and safety outcomes involving the use of the company's Combo Dual Therapy Stent when compared to the TAXUS(®) Liberte(®) paclitaxel-eluting stent. The data were presented by Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, at EuroPCR 2012. In the 12-month follow-up data set, the clinically driven...

2012-05-02 10:28:03

Basis for the epilepsy-autism connection is found - and may be reversible with an existing drug BOSTON, May 2, 2012 /PRNewswire-USNewswire/ -- Early-life seizures are known to be associated with autism, and studies indicate that about 40 percent of patients with autism also have epilepsy. A study from Boston Children's Hospital finds a reason for the link, and suggests that an existing drug, already shown to be safe in children, could help prevent autism from developing in...

2012-05-02 15:07:00

IDIBELL researchers discover that combining two mTOR inhibitors cause the regression of hepatocellular carcinoma The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumor cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine. Primary liver cancer or...

2012-05-01 21:18:47

Scientists at Joslin Diabetes Center have identified a key mechanism of action for the TOR (target of rapamycin) protein kinase, a critical regulator of cell growth which plays a major role in illness and aging. This finding not only illuminates the physiology of aging but could lead to new treatments to increase lifespan and control age-related conditions, such as cancer, type 2 diabetes, and neurodegeneration. Over the past decade, studies have shown that inhibiting TOR activity, which...

Study Reveals Why Rapamycin Causes Diabetes-like Symptoms
2012-04-04 11:01:49

Rapamycin is an immunosuppressant derived from bacteria found on Easter Island. It was approved for organ transplant patients by the FDA in 1999. The drug helps to prevent organ rejection and is currently undergoing clinical trials as a cancer treatment. It shows promise for its anti-cancer activity and may even slow the aging process. Pere Puigserver of Dana-Farber Cancer Institute says, “This is a drug that is pretty well known for its benefits. Rapamycin is one of the few drugs,...

2012-04-02 15:53:36

Aberrations in translation regulators associated with hormone receptor-positive disease survival Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012. All of the aberrantly activated translational proteins are regulated by the PI3K/mTOR molecular signaling pathway, which has been implicated in...

2012-04-02 09:09:21

Researchers control drug side effects for treatment gains in Phase I trial A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012. Five of 17 Ewing's sarcoma patients responded to the combination, with two achieving complete responses, one for 27 weeks. The...